Autopsy report · NCT03782363
Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.
Cause of deathOther
“Initial version of the protocol not submitted and new version approved has a new sponsor and it has been added into Clinicaltrials by the new sponsor”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 1
- Sponsor
- Italian Sarcoma Group
- Sponsor type
- University, hospital or other
- Conditions
- Sarcoma
- Interventions
- Autologous CIK Dose level 1; Autologous CIK Dose level 2; Autologous CIK Dose level 3; Autologous CIK Dose level 4
- Participants
- 0
- Sites
- 1
- Countries
- Italy
Trials that died the same way
- Optimized Caloric-proteic Nutrition in Septic and Septic Shock Patients
“The protocol was modified substantially and will be resubmitted to Clinical Trial” - Angiotensin II vs. Vasopressin in Septic Shock
“Funding and protocol changes. Replaced with new pilot trial.” - BreathID Multi-center HCV Liver Breath Test Study
“Due to FDA comments, protocol changed; new trial will be proposed shortly” - Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)
“The sponsor is pursuing a different product for this indication” - A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors
“The sponsor adjusts the clinical development strategy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.